MPC-11 Syngeneic Model Service for Multiple Myeloma (MM)

The MPC-11 syngeneic model of multiple myeloma propagates an IgG2b-secreting murine plasmacytoma with constitutive IL-6 production in fully immunocompetent BALB/c hosts—a founding line of antibody-secretion biology and a proven peritoneal-dissemination platform. Alfa Cytology delivers the complete MPC-11 workflow—density-controlled cell banking, subcutaneous or intraperitoneal inoculation, tumor- and nodule-based monitoring, scheduled dosing and dissemination-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of MPC-11 Syngeneic Model for Multiple Myeloma (MM)

MPC-11’s story is intertwined with the birth of antibody-secretion science. The line descends from the Merwin plasma cell tumor-II, carried in BALB/c mice, and was adapted to culture by Laskov and Scharff—whose 1970–1971 papers in the Journal of Experimental Medicine and Journal of Molecular Biology established it as the paradigm for how plasma cells synthesize, assemble and secrete gamma globulin. The cells secrete fully assembled IgG2b at five to six picograms per cell per minute, alongside assembly intermediates—half molecules, light-chain dimers and free light chains—that made the line indispensable for studying secretion pathways; Coffino’s accompanying Science report used MPC-11 to devise the first quantitative method for detecting immunoglobulin-variants. Molecularly, the line carries a second distinction: it produces interleukin-6 constitutively, and Blankenstein’s 1990 demonstration that a DNA rearrangement drives that expression made MPC-11 a landmark in cytokine dysregulation research. Cytogenetically it is hypotetraploid with a modal number of 67–70, contains A-type viral particles—a period signature handled at Hazard Group 2—and displays a singular culture identity: horse serum rather than fetal bovine serum, with cultures maintained between 2 × 10⁵ and 9 × 10⁵ cells per mL.

Fig 1. In vivo dose-dependence and growth kinetics of subcutaneous MPC-11 tumors in syngeneic BALB/c mice, showing tumor-bearing percentage over days after injection of 10³–10⁵ cells as a readout of mesenchymal stromal effects on plasmacytoma growth. (Shoham, T., et al., 2001)

In vivo, MPC-11 offers two clean formats. Subcutaneously, two hundred thousand cells in the flank produce palpable nodules within seven days—the treatment window used in the classic polyclonal-antibody study, where a rabbit anti-murine-plasmacytoma-globulin reagent drove forty-eight percent of cells into apoptosis with caspase-3, -8 and -9 activation, shrank both subcutaneous and intraperitoneal disease and prolonged survival. Intraperitoneally, two million cells seed the cavity with some three dozen nodules dispersed around the small bowel, mesentery and diaphragm—a dissemination pattern read out by simple nodule counting that remains one of the most economical peritoneal-carcinomatosis-style formats in myeloma research. The line also contributed early evidence that plasmacytomas carry tumor-associated antigens recognizable by cytotoxic T cells. Caveats: the horse-serum culture and density window demand discipline; isotype heterogeneity can appear (IgG2a and kappa variants are documented alongside the expected IgG2b); A-type particles require appropriate handling; and the two formats model quite different disease patterns, so choice should follow the scientific question.

Cell Line Information: MPC-11

Key characteristics of MPC-11 are summarized below.

Our Services

With in vivo hematology-oncology and antibody-biology specialists guiding each stage and pathology, ELISA and flow-cytometry capabilities in-house, Alfa Cytology molds every MPC-11 engagement around the sponsor’s question—selecting subcutaneous or peritoneal formats, enforcing horse-serum culture and density control, and pairing dosing with tumor- and nodule-based readouts for clean, decision-grade preclinical data.

Workflow of MPC-11 Syngeneic Model Construction

Construction of the MPC-11 syngeneic model is an inoculation workflow whose quality rests on density-controlled cells, strain-matched recipients and disciplined monitoring. A standard engagement proceeds as follows:

1. Source and qualify cells: MPC-11 stocks are cleared by mycoplasma PCR and identity-verified, with IgG2b productivity documented as a functional baseline; culture density history is reviewed (maintenance at 2–9 × 10⁵ cells/mL), and luciferase labeling is titrated in vitro where imaging readouts are required.
2. Prepare recipients: BALB/c mice (typically 6–8 weeks old) complete acclimation and health screening and are individually marked before inoculation.
3. Prepare the inoculum: log-phase cells within the validated density window are washed free of horse serum, counted, checked for viability and resuspended in PBS (2 × 10⁵ cells for flank implants; 2 × 10⁶ cells for peritoneal dissemination).
4. Inoculate: cells are injected subcutaneously into the flank or intraperitoneally, with consistent technique so that nodule geometry stays reproducible for counting.
5. Assign groups: flank-format animals are randomized when nodules reach palpability (classically day 7); peritoneal-format animals are randomized around day 5, balanced by body weight.
6. Dose and follow: test articles are administered on schedule; flank tumors are measured with calipers (volume = length × breadth² ÷ 2), while peritoneal cohorts are followed by body weight, abdominal girth and clinical status; survival is the primary endpoint.
7. Terminate and analyze: tumors are resected and weighed (or peritoneal nodules counted); spleen and ascites are recorded; histopathology confirms plasmacytoma morphology; IgG2b is quantified as a tumor-burden biomarker; flow cytometry and immunohistochemistry complete the package.

Fig 2. MPC-11 Syngeneic Model construction workflow.

Case Study-MPC-11 Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the MPC-11 platform: establishment-phase density-control validation, in vivo tracking of subcutaneous and peritoneal formats, antibody- and drug-based intervention studies, and systematic endpoint analyses covering nodule counts, histopathology, immunoglobulin quantification and survival. Representative growth curves, nodule-count datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

MPC-11’s horse-serum culture, density window and dual formats reward specialists who respect its quirks—which is where Alfa Cytology invests:

• Horse-serum, density-controlled banking that honors the line’s unusual culture identity.
• Dual-format execution spanning subcutaneous and peritoneal dissemination designs in BALB/c hosts.
• Nodule-count readout expertise for the economical peritoneal format.
• Immunoglobulin-productivity baselines (5–6 pg IgG2b per cell per minute) as a functional identity check.
• Antibody-therapy evaluation reflecting the documented PAb apoptosis/caspase precedent.
• Hazard Group 2 handling discipline for A-type-particle-containing stocks.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the MPC-11 syngeneic multiple myeloma model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.